Assessing Zealand Pharma (CPSE:ZEAL) Valuation After Petrelintide Phase 2 Data And Sharp Share Price Drop

Zealand Pharma (CPSE:ZEAL) is under close watch after Phase 2 topline data for obesity drug candidate petrelintide triggered a sharp share price drop, despite meeting the trial’s primary weight loss and safety goals.

See our latest analysis for Zealand Pharma.

The sharp 1 day share price return of 36.4% and 7 day share price return of 36.1% have reversed much of Zealand Pharma’s earlier gains. However, the 3 year total shareholder return of 4.9% and 5 year total shareholder return of 23.7% still leave longer term holders ahead overall, suggesting momentum has clearly faded since the Phase 2 petrelintide update.

If this petrelintide news has you reassessing biotech opportunities, it could be a good time to widen your watchlist with 119 healthcare AI stocks and see what else is on the move.

With Zealand Pharma shares giving up much of their recent gains and petrelintide still progressing toward later stage trials, the key question now is whether the current valuation underestimates the pipeline or whether the market already reflects future growth.

Most Popular Narrative: 67.8% Undervalued

With Zealand Pharma last closing at DKK234.90 against a widely followed fair value estimate of DKK730.07, the narrative implies a wide valuation gap that hinges on how its obesity and metabolic pipeline plays out.

The analysts have a consensus price target of DKK835.467 for Zealand Pharma based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of DKK1120.0, and the most bearish reporting a price target of just DKK400.0.

Read the complete narrative.

Want to see what sits beneath that wide range of targets? The narrative focuses on sharp shifts in revenue, margins and a future earnings multiple that is anything but ordinary.

Result: Fair Value of DKK730.07 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, the story can shift quickly if key obesity trials disappoint or if partner milestones and royalties fall short of expectations, which would put that optimistic earnings path under pressure.

Find out about the key risks to this Zealand Pharma narrative.

Next Steps

If this mix of optimism and concern around Zealand Pharma feels finely balanced, consider acting while the details are still fresh and shape your own view with 3 key rewards and 3 important warning signs.

Looking for more investment ideas?

If this Zealand Pharma story has sharpened your thinking, do not stop here. Widen your search now or you risk missing other compelling opportunities on your radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com